Brind.

AstraZeneca gained global rights to TQC3721 outside China, while Merck acquired the developer of Ohtuvayre, a drug challenging in COPD treatment.

1 report, 1 independent Updated Jul 9

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

AstraZeneca Verona Pharma MSD

Keep exploring

The entities involved

AstraZeneca
British-Swedish pharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Mon 11:04
- Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.Sat 18:52
Verona Pharma
company in London, United Kingdom

Nothing else this week.
MSD
company in Rome, Italy
- MSD, which operates as Merck & Co. in the US and Canada, has appointed Vidhya as Associate Vice President.Mon 12:02
- MSD and Aurobindo Pharma signed a voluntary licensing agreement for generic alimatravir.Mon 05:30

Coverage

Newest first; wire copies grouped

Jul 9bioxconomy.com